CryoCor completes trial enrolment:
This article was originally published in Clinica
Executive Summary
CryoCor has completed enrolment of more than 170 patients in a 12-month pivotal clinical study to assess the use of its cryoablation technology in atrial fibrillation. The device, also named CryoCor, was recently approved in the US for the treatment of right atrial flutter (see Clinica No 1268, p 2). The San Diego, California-based company said that it expected to file a PMA for the treatment of atrial fibrillation in late 2008, with approval anticipated in 2009.
You may also be interested in...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.